Senexin Program (Lead)

About Senex Biotechnology

Senex Biotechnology, founded in 2005, is a private, preclinical-stage biotech company targeting cancer drug resistance and metastasis through a novel biological pathway associated with cellular senescence. Its core platform, born from founder Igor Roninson's academic research, identifies unique drug targets required by tumor cells but not normal tissues. The lead program, a highly selective small-molecule inhibitor, is anticipated to enter clinical trials within a year for difficult-to-treat cancers. The company has a strong grant-funded foundation, with 16 awards from entities like the NIH and DoD, and is led by a seasoned team with deep expertise in oncology drug development.

Therapeutic Areas